Gene therapy for duchenne muscular dystrophy: Expectations and challenges

Archives of Neurology

Volumn 64, Issue 9, 2007, Pages 1236-1241

  Rodino Klapac, Louise R ^b   Chicoine, Louis G ^b   Kaspar, Brian K ^b   Mendell, Jerry R ^a  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTISENSE OLIGODEOXYNUCLEOTIDE; DYSTROPHIN; PARVOVIRUS VECTOR; PTC 124; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANTISENSE THERAPY; CLINICAL TRIAL; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM;

DNA; DYSTROPHIN; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENOUS; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; VIRUSES;

EID: 34548602367     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.9.1236     Document Type: Review

References (48)

1. Emery AE. Population frequency of inherited neuromuscular diseases: a world survey. Neuromuscul Disord. 1991;1(1):19-29.
2. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-928.
3. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50(3):509-517.
4. Sinha S, Mishra S, Singh V, Mittal RD, Mittal B. High frequency of new mutations in North Indian Duchenne/Becker muscular dystrophy patients. Clin Genet. 1996;50(5):327-331.
5. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989;320(24):1592-1597.
6. Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med. 1998;4(12):1441-1444.
7. Bogdanovich S, Krag TO, Barton ER, et al. Functional improvements of dystrophic muscle by myostatin blockade. Nature. 2002;420(6914):418-421.
8. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001;138(1):45-50.
9. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade [published online ahead of print March 20, 2006]. Neuromuscul Disord. 2006;16(4):249-255. doi:10.1016/j.nmd.2006.01.010.
10. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005;84(11):843-850.
11. Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GT, van Deutekom JC. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther. 2006;14(3):401-407.
12. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD [published online ahead of print May 25, 2006]. Gene Ther. 2006;13(19):1373-1381.
13. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999;104(4):375-381.
14. Hamed SA. Drug evaluation: PTC-124 - a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs. 2006;9(11):783-789.
15. Liang KW, Nishikawa M, Liu F, Sun B, Ye O, Huang L. Restoration of dystrophin expression in mdx mice by intravascular injection of naked DNA containing full-length dystrophin cDNA. Gene Ther. 2004;11(11):901-908.
16. Scott JM, Li S, Harper SQ, et al. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul Disord. 2002;12(suppl 1):S23-S29.
17. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 1996;2(5):545-550.
18. Hartigan-O'Connor D, Barjot C, Crawford R, Chamberlain JS. Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection. Hum Gene Ther. 2002;13(4):519-531.
19. Verma IM. A tumultuous year for gene therapy [editorial]. Mol Ther. 2000;2(5):415-416.
20. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005;5(3):285-297.
21. Schnepp BC, Jensen RL, Chen CL, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol. 2005;79(23):14793-14803.
22. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors [published online ahead of print July 25, 2004]. Nat Med. 2004;10(8):828-834. doi:10.1038/nm1085.
23. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73(5):3994-4003.
24. Wang Z, Zhu T, Qiao C, et al. Adeno-associated serotype 8 efficiently delivers genes to muscle and heart [published online ahead of print February 27, 2005]. Nat Biotechnol. 2005;23(3):321-328. doi:10.1038/nbt1073.
25. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol. 2003;77(6):3495-3504.
26. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A. 1990;87(6):2211-2215.
27. Davé UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science. 2004;303(5656):333.
28. Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adeno associated virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood. 2006;108(10):3321-3328.
29. Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice [published online ahead of print October 25, 2005]. Blood. 2006;107(5):1810-1817. doi:10.1182/blood-2005-08-3229.
30. Hodges BL, Taylor KM, Chu Q, et al. Local delivery of a viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver [published online ahead of print August 31, 2005] Mol Ther. 2005;12(6):1043-1051. doi:10.1016/j.ymthe.2005.06.475.
31. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response [published correction appears in Nat Med. 2006;12(5):592] [published online ahead of print February 12, 2006] Nat Med. 2006;12(3):342-347. doi:10.1038/nm1358.
32. Rock KL. Exiting the outside world for cross-presentation. Immunity. 2006;25(4):523-525.
33. Straub V, Campbell KP. Muscular dystrophies and the dystrophin- glycoprotein complex. Curr Opin Neurol. 1997;10(2):168-175.
34. Blake DJ, Tinsley JM, Davies KE. Utrophin: a structural and functional comparison to dystrophin. Brain Pathol. 1996;6(1):37-47.
35. England SB, Nicholoson LV, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343(6254):180-182.
36. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8(3):253-261.
37. Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehnerf SC, Chamberlain JS. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol. 2000;150(6):1399-1410. doi:10.1083/jcb.150.6.1399.
38. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A. 2000;97(25):13714-13719.
39. Watchko J, O'Day T, Wang B, et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther. 2002;13(12):1451-1460. doi:10.1089/10430340260185085.
40. Liu M, Harper SQ, Grange RW, Chamberlin JS, Duan D. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther. 2005;11(2):245-256.
41. Abmayr S, Gregorevic P, Allen JM, Chamerlain JS. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. Mol Ther. 2005;12(3):441-450.
42. Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci U S A. 2002;99(8):5616-5621. doi/10.1073/pnas.082613599.
43. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther. 1998;9(18):2745-2760.
44. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther. 1995;6(10):1329-1341.
45. Inoue N, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol. 1998;72(9):7024-7031.
46. Tamayose K, Hirai Y, Shimada T. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther. 1996;7(4):507-513.
47. Wagner JA, Messner AH, Moran ML, et al. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAVCFTR) in the cystic fibrosis maxillary sinus. Laryngoscope. 1999;109(2, pt 1):266-274.
48. Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 1998;351(9117):1702- 1703.